Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance

Cassava Sciences IncTrade
Health Care Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Health Care Select Sector SPDR Fund — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Health Care Select Sector SPDR Fund trades at $168.21. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNAXLV
Market Cap
$47.75M
Sector
Health
52-Week High
$4.64$168.44
52-Week Low
$0.87$131.16
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Health Care Select Sector SPDR Fund

XLV, the Health Care Select Sector SPDR ETF, trades at $168.44 with a neutral daily change. Technical indicators show a bullish trend from moving averages but oscillators are neutral, with the 6-day RSI at 86.78 suggesting overbought conditions. The fund's low 0.08% expense ratio and defensive healthcare sector exposure attract steady inflows amid market volatility, as highlighted by recent ETF flow reports.

The outlook for XLV is cautiously optimistic, supported by defensive demand and strong sector earnings. Key opportunities include diversification benefits and cost efficiency, while risks involve sector-specific regulatory pressures and broader economic sensitivity. Investors should weigh the ETF's stability against potential growth limitations in a concentrated portfolio.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Health Care Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Read more on XLV